Spontaneous pneumothorax-associated with genetic disorders
Therapeutic Advances in Respiratory Disease · Published 2026-03-01 · DOI 10.1177/17534666261437339
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/17534666261437339
Abstract
Spontaneous pneumothorax (SP) is defined by the presence of air in the pleural space arising from neither trauma nor iatrogenic causes. It can develop secondary to various etiologies. The familial clustering observed in some patients with SP supports the view that genetic factors play a role in the pathogenesis of SP. Several recognizable pneumothorax-associated genetic syndromes exist, including Birt-Hogg-Dubé syndrome (BHD), tuberous sclerosis complex-associated lymphangioleiomyomatosis (TSC-LAM), Marfan syndrome (MFS), cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), vascular Ehlers-Danlos syndrome (vEDS), Loeys-Dietz syndrome (LDS), and a few others. Recognition of these syndromes underlying SP facilitates optimal management and counseling regarding prognosis and potential comorbidities. In this review, we systematically summarize several genetic syndromes associated with pneumothorax, in which SP may manifest either as an initial presenting symptom or as a potential complication that adversely affects the prognosis.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Pulmonary tuberculosis during the developmental period contributes to COPD and pre-COPD in mid-to-late adulthood: a retrospective cohort study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The association between mental health, cognitive functioning, and health-related quality of life in adults with chronic nontuberculous mycobacterial pulmonary disease · Therapeutic Advances in Respiratory Disease · 2025 · Same journal